For stage III cancer, the 5-year OS was 88.1% for patients with high EEF1A1 expression and 62.6% for those with low EEF1A1 (p = 0.030, HR = 2.22, 95% CI = 1.06–4.50) (Figure 4a). The gene discussed is EEF1A1; the disease is cancer.